BACKGROUND: Previous reports show that addition of omalizumab to standard therapy
reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids …

Despite the expansion of the understanding in asthma pathophysiology and the continual
advances in disease management, a small subgroup of patients remain partially controlled …

The implications of boosting Omalizumab treatment (OT) in patients with severe allergic
asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month …

Introduction: Efficacy and safety of omalizumab in patients with severe allergic asthma has
been established in both randomized controlled trials and real-life studies Aim: To evaluate …

The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

Severe persistent asthma causes a substantial morbidity and mortality burden and is
frequently inadequately controlled despite intensive guideline-based therapy. Targeting …

Objectives: The aim of this study was to assess the stability of the effectiveness of
omalizumab as add-on treatment in 11 patients with severe persistent allergic asthma …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …